Machine learning-, rule- and pharmacophore-based classification on the inhibition of P-glycoprotein and NorA

Abstract The efflux pumps P-glycoprotein (P-gp) in humans and NorA in Staphylococcus aureus are of great interest for medicinal chemists because of their important roles in multidrug resistance (MDR). The high polyspecificity as well as the unavailability of high-resolution X-ray crystal structures of these transmembrane proteins lead us to combining ligand-based approaches, which in the case of this study were machine learning, perceptual mapping and pharmacophore modelling. For P-gp inhibitory activity, individual models were developed using different machine learning algorithms and subsequently combined into an ensemble model which showed a good discrimination between inhibitors and noninhibitors (acctrain-diverse = 84%; accinternal-test = 92% and accexternal-test = 100%). For ligand promiscuity between P-gp and NorA, perceptual maps and pharmacophore models were generated for the detection of rules and features. Based on these in silico tools, hit compounds for reversing MDR were discovered from the in-house and DrugBank databases through virtual screening in an attempt to restore drug sensitivity in cancer cells and bacteria.

[1]  W. Youden,et al.  Index for rating diagnostic tests , 1950, Cancer.

[2]  K. Danø.  Active outward transport of daunomycin in resistant Ehrlich ascites tumor cells. , 1973, Biochimica et biophysica acta.

[3]  Geoffrey E. Hinton,et al.  A general framework for parallel distributed processing , 1986 .

[4]  James L. McClelland,et al.  Parallel distributed processing: explorations in the microstructure of cognition, vol. 1: foundations , 1986 .

[5]  M. Melamed,et al.  Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. , 1990, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[6]  D. Hooper,et al.  Quinolone resistance mediated by norA: physiologic characterization and relationship to flqB, a quinolone resistance locus on the Staphylococcus aureus chromosome , 1994, Antimicrobial Agents and Chemotherapy.

[7]  G. Kaatz,et al.  Mechanisms of fluoroquinolone resistance in genetically related strains of Staphylococcus aureus , 1997, Antimicrobial agents and chemotherapy.

[8]  C. Wermuth,et al.  Glossary of terms used in medicinal chemistry (IUPAC Recommendations 1998) , 1998 .

[9]  J. Verhoef,et al.  The effect of reserpine, an inhibitor of multidrug efflux pumps, on the in-vitro activities of ciprofloxacin, sparfloxacin and moxifloxacin against clinical isolates of Staphylococcus aureus. , 1998, The Journal of antimicrobial chemotherapy.

[10]  H. Preisler,et al.  A phase I and pharmacokinetic study of CBT-1 as a multidrug resistance modulator in the treatment of patients with advanced cancer. , 1998, Cancer biotherapy & radiopharmaceuticals.

[11]  R. Kim,et al.  P-glycoprotein and cytochrome P-450 3A inhibition: dissociation of inhibitory potencies. , 1999, Cancer research.

[12]  G. Kaatz,et al.  Effects of NorA Inhibitors on In Vitro Antibacterial Activities and Postantibiotic Effects of Levofloxacin, Ciprofloxacin, and Norfloxacin in Genetically Related Strains ofStaphylococcus aureus , 1999, Antimicrobial Agents and Chemotherapy.

[13]  R. Oldham,et al.  Phase I study of CBT-1 and Taxol in patients with Taxol resistant cancers. , 2000, Cancer biotherapy & radiopharmaceuticals.

[14]  G. Lehne,et al.  P-glycoprotein as a drug target in the treatment of multidrug resistant cancer. , 2000, Current drug targets.

[15]  M. Tanaka,et al.  Mechanism of quinolone resistance in Staphylococcus aureus , 2000, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[16]  S. Ekins,et al.  Three-dimensional quantitative structure-activity relationships of inhibitors of P-glycoprotein. , 2002, Molecular pharmacology.

[17]  E. Schuetz,et al.  Interaction of Cytochrome P450 3A Inhibitors with P-Glycoprotein , 2002, Journal of Pharmacology and Experimental Therapeutics.

[18]  M. Delaforge,et al.  Characterization of two pharmacophores on the multidrug transporter P-glycoprotein. , 2002, Molecular pharmacology.

[19]  S. Ekins,et al.  Application of three-dimensional quantitative structure-activity relationships of P-glycoprotein inhibitors and substrates. , 2002, Molecular pharmacology.

[20]  G. Kaatz.  Inhibition of bacterial efflux pumps: a new strategy to combat increasing antimicrobial agent resistance , 2002, Expert opinion on emerging drugs.

[21]  Tingjun Hou,et al.  ADME evaluation in drug discovery , 2002, Journal of molecular modeling.

[22]  I. Pajeva,et al.  Pharmacophore model of drugs involved in P-glycoprotein multidrug resistance: explanation of structural variety (hypothesis). , 2002, Journal of medicinal chemistry.

[23]  G. Kaatz,et al.  A novel inhibitor of multidrug efflux pumps in Staphylococcus aureus. , 2003, The Journal of antimicrobial chemotherapy.

[24]  M. Abou‐Donia,et al.  A Role for P-Glycoprotein in Environmental Toxicology , 2003, Journal of toxicology and environmental health. Part B, Critical reviews.

[25]  M. Fromm,et al.  Importance of P‐glycoprotein for drug disposition in humans , 2003, European journal of clinical investigation.

[26]  T. Grossman,et al.  Inhibition of Antibiotic Efflux in Bacteria by the Novel Multidrug Resistance Inhibitors Biricodar (VX-710) and Timcodar (VX-853) , 2004, Antimicrobial Agents and Chemotherapy.

[27]  L. Pardo,et al.  SAR studies of dihydro-beta-agarofuran sesquiterpenes as inhibitors of the multidrug-resistance phenotype in a Leishmania tropica line overexpressing a P-glycoprotein-like transporter. , 2004, Journal of medicinal chemistry.

[28]  G. Ecker,et al.  Lead Identification for Modulators of Multidrug Resistance based on in silico Screening with a Pharmacophoric Feature Model , 2004, Archiv der Pharmazie.

[29]  B. Marquez.  Bacterial efflux systems and efflux pumps inhibitors. , 2005, Biochimie.

[30]  B. Everitt.  Multidimensional Scaling and Correspondence Analysis , 2005 .

[31]  Scott D. Kahn,et al.  Current Status of Methods for Defining the Applicability Domain of (Quantitative) Structure-Activity Relationships , 2005, Alternatives to laboratory animals : ATLA.

[32]  Ling Yang,et al.  Classification of Substrates and Inhibitors of P-Glycoprotein Using Unsupervised Machine Learning Approach , 2005, J. Chem. Inf. Model..

[33]  T. Dupree,et al.  Pharmacophore development and validation for inhibitors of the bacterial NorA efflux pump , 2005 .

[34]  Nina Nikolova-Jeliazkova,et al.  QSAR Applicability Domain Estimation by Projection of the Training Set in Descriptor Space: A Review , 2005, Alternatives to laboratory animals : ATLA.

[35]  Christoph Globisch,et al.  Molecular Modeling of P-Glycoprotein and Related Drugs , 2005, Medicinal Chemistry Research.

[36]  Hongmao Sun.  A naive bayes classifier for prediction of multidrug resistance reversal activity on the basis of atom typing. , 2005, Journal of medicinal chemistry.

[37]  J. Polli,et al.  IN VITRO P-GLYCOPROTEIN INHIBITION ASSAYS FOR ASSESSMENT OF CLINICAL DRUG INTERACTION POTENTIAL OF NEW DRUG CANDIDATES: A RECOMMENDATION FOR PROBE SUBSTRATES , 2006, Drug Metabolism and Disposition.

[38]  Ashwani Kumar,et al.  Piperine, a Phytochemical Potentiator of Ciprofloxacin against Staphylococcus aureus , 2006, Antimicrobial Agents and Chemotherapy.

[39]  I. Poggesi,et al.  Computational models for identifying potential P-glycoprotein substrates and inhibitors. , 2006, Molecular pharmaceutics.

[40]  Praveen M. Bahadduri,et al.  Rapid Identification of P-glycoprotein Substrates and Inhibitors , 2006, Drug Metabolism and Disposition.

[41]  M. Gottesman,et al.  Targeting multidrug resistance in cancer , 2006, Nature Reviews Drug Discovery.

[42]  T. Ozben.  Mechanisms and strategies to overcome multiple drug resistance in cancer , 2006, FEBS letters.

[43]  David S. Wishart,et al.  DrugBank: a comprehensive resource for in silico drug discovery and exploration , 2005, Nucleic Acids Res..

[44]  Paola Gramatica,et al.  Principles of QSAR models validation: internal and external , 2007 .

[45]  B. Everitt.  An R and S-Plus® Companion to Multivariate Analysis , 2007 .

[46]  M. Fromm,et al.  Role of P-Glycoprotein Inhibition for Drug Interactions , 2007, Clinical pharmacokinetics.

[47]  L. Pardo,et al.  Biological evaluation, structure-activity relationships, and three-dimensional quantitative structure-activity relationship studies of dihydro-beta-agarofuran sesquiterpenes as modulators of P-glycoprotein-dependent multidrug resistance. , 2007, Journal of medicinal chemistry.

[48]  W. Gansterer,et al.  Predictive QSAR Models for Polyspecific Drug Targets: The Importance of Feature Selection , 2008 .

[49]  Gerhard F. Ecker,et al.  Classification Models for hERG Inhibitors by Counter‐Propagation Neural Networks , 2008, Chemical biology & drug design.

[50]  S. C. Taneja,et al.  Novel structural analogues of piperine as inhibitors of the NorA efflux pump of Staphylococcus aureus. , 2008, The Journal of antimicrobial chemotherapy.

[51]  C. Avendaño,et al.  Drugs That Modulate Resistance to Antitumor Agents , 2008 .

[52]  Ying Sun,et al.  Design, synthesis, cytoselective toxicity, structure-activity relationships, and pharmacophore of thiazolidinone derivatives targeting drug-resistant lung cancer cells. , 2008, Journal of medicinal chemistry.

[53]  David S. Wishart,et al.  DrugBank: a knowledgebase for drugs, drug actions and drug targets , 2007, Nucleic Acids Res..

[54]  Christoph Globisch,et al.  Combined Pharmacophore Modeling, Docking, and 3D QSAR Studies of ABCB1 and ABCC1 Transporter Inhibitors , 2009, ChemMedChem.

[55]  K. Roy,et al.  On Two Novel Parameters for Validation of Predictive QSAR Models , 2009, Molecules.

[56]  Ian H. Witten,et al.  The WEKA data mining software: an update , 2009, SKDD.

[57]  H. Nikaido.  Multidrug resistance in bacteria. , 2009, Annual review of biochemistry.

[58]  Ling Zhang,et al.  Efflux Pump Inhibitors: A Strategy to Combat P‐Glycoprotein and the NorA Multidrug Resistance Pump , 2010, ChemMedChem.

[59]  Jun Huan,et al.  COMPARISON OF CHEMICAL DESCRIPTORS FOR PROTEIN–CHEMICAL INTERACTION PREDICTION , 2010 .

[60]  T. Langer.  Pharmacophores in Drug Research , 2010, Molecular informatics.

[61]  Miguel X. Fernandes,et al.  Pharmacophore-Based Screening as a Clue for the Discovery of New P-Glycoprotein Inhibitors , 2010, IWPACBB.

[62]  Ling Zhang,et al.  Efflux Pump Inhibitors: A Strategy to Combat P-Glycoprotein and the NorA Multidrug Resistance Pump , 2010 .

[63]  Ricardo J. Ferreira,et al.  Toward a Better Pharmacophore Description of P-Glycoprotein Modulators, Based on Macrocyclic Diterpenes from Euphorbia Species , 2011, J. Chem. Inf. Model..

[64]  David S. Wishart,et al.  DrugBank 3.0: a comprehensive resource for ‘Omics’ research on drugs , 2010, Nucleic Acids Res..

[65]  M. Zeitlinger,et al.  The third-generation P-glycoprotein inhibitor tariquidar may overcome bacterial multidrug resistance by increasing intracellular drug concentration. , 2011, The Journal of antimicrobial chemotherapy.

[66]  Tudor I. Oprea,et al.  A novel approach for predicting P-glycoprotein (ABCB1) inhibition using molecular interaction fields. , 2011, Journal of medicinal chemistry.

[67]  Matthew P. Jacobson,et al.  Predicting Binding to P-Glycoprotein by Flexible Receptor Docking , 2011, PLoS Comput. Biol..

[68]  E. Proschak,et al.  Structure‐Based Pharmacophores for Virtual Screening , 2011, Molecular informatics.

[69]  Lei Chen,et al.  ADME evaluation in drug discovery. 10. Predictions of P-glycoprotein inhibitors using recursive partitioning and naive Bayesian classification techniques. , 2011, Molecular pharmaceutics.

[70]  P. Willett,et al.  PHARMACOPHORE PERCEPTION , DEVELOPMENT , AND USE IN DRUG DESIGN , 2011 .

[71]  CHUN WEI YAP,et al.  PaDEL‐descriptor: An open source software to calculate molecular descriptors and fingerprints , 2011, J. Comput. Chem..

[72]  M. X. Fernandes,et al.  New Uses for Old Drugs: Pharmacophore‐Based Screening for the Discovery of P‐Glycoprotein Inhibitors , 2011, Chemical biology & drug design.

[73]  Lei Chen,et al.  Computational models for predicting substrates or inhibitors of P-glycoprotein. , 2012, Drug discovery today.

[74]  Max K. Leong,et al.  Prediction of Promiscuous P-Glycoprotein Inhibition Using a Novel Machine Learning Scheme , 2012, PloS one.

[75]  H. Nikaido,et al.  Broad-specificity efflux pumps and their role in multidrug resistance of Gram-negative bacteria. , 2012, FEMS microbiology reviews.

[76]  J. P. Sharma,et al.  Capsaicin, a novel inhibitor of the NorA efflux pump, reduces the intracellular invasion of Staphylococcus aureus. , 2012, The Journal of antimicrobial chemotherapy.

[77]  A. Bianucci,et al.  Development of Classification Models for Identifying “True” P-glycoprotein (P-gp) Inhibitors Through Inhibition, ATPase Activation and Monolayer Efflux Assays , 2012, International journal of molecular sciences.

[78]  A. Palmeira,et al.  Three decades of P-gp inhibitors: skimming through several generations and scaffolds. , 2012, Current medicinal chemistry.

[79]  G. Cruciani,et al.  Ligand Promiscuity between the Efflux Pumps Human P-Glycoprotein and S. aureus NorA. , 2012, ACS medicinal chemistry letters.

[80]  M. X. Fernandes,et al.  Structure and ligand-based design of P-glycoprotein inhibitors: a historical perspective. , 2012, Current pharmaceutical design.

[81]  Po Ughachukwu,et al.  Efflux Pump-Mediated Resistance in Chemotherapy , 2012, Annals of medical and health sciences research.

[82]  S. Steinberg,et al.  A pharmacodynamic study of the P-glycoprotein antagonist CBT-1® in combination with paclitaxel in solid tumors. , 2012, The oncologist.

[83]  Vasanthanathan Poongavanam,et al.  Fingerprint-based in silico models for the prediction of P-glycoprotein substrates and inhibitors , 2012, Bioorganic & medicinal chemistry.

[84]  P. Lakshmi,et al.  Overview of P-glycoprotein inhibitors: a rational outlook , 2012 .

[85]  Songthip Ounpraseuth,et al.  Estimating misclassification error: a closer look at cross-validation based methods , 2012, BMC Research Notes.

[86]  G. Kaatz,et al.  Expression of multidrug resistance efflux pump genes in clinical and environmental isolates of Staphylococcus aureus. , 2012, International journal of antimicrobial agents.

[87]  Michael R Hamblin,et al.  Send Orders of Reprints at Reprints@benthamscience.net Microbial Efflux Systems and Inhibitors: Approaches to Drug Discovery and the Challenge of Clinical Implementation , 2022 .

[88]  L. Amaral,et al.  Send Orders of Reprints at Reprints@benthamscience.net Multidrug Efflux Pumps in Staphylococcus Aureus: an Update , 2022 .

[89]  J. Handzlik,et al.  Recent Advances in Multi-Drug Resistance (MDR) Efflux Pump Inhibitors of Gram-Positive Bacteria S. aureus , 2013, Antibiotics.

[90]  K. Thai,et al.  Pharmacophore modeling for antitargets. , 2013, Current topics in medicinal chemistry.

[91]  Ajay Kumar,et al.  Osthol and curcumin as inhibitors of human Pgp and multidrug efflux pumps of Staphylococcus aureus: reversing the resistance against frontline antibacterial drugs , 2014 .

[92]  David S. Wishart,et al.  DrugBank 4.0: shedding new light on drug metabolism , 2013, Nucleic Acids Res..

[93]  A. Saneja,et al.  Co-formulation of P-glycoprotein Substrate and Inhibitor in Nanocarriers: An Emerging Strategy for Cancer Chemotherapy. , 2014, Current cancer drug targets.

[94]  Girinath G. Pillai,et al.  In silico machine learning methods in drug development. , 2014, Current topics in medicinal chemistry.

[95]  Gerhard F. Ecker,et al.  Ligand and Structure-Based Classification Models for Prediction of P-Glycoprotein Inhibitors , 2013, J. Chem. Inf. Model..

[96]  G. Ecker,et al.  Synthesis, biological evaluation and 3D-QSAR studies of new chalcone derivatives as inhibitors of human P-glycoprotein. , 2014, Bioorganic & medicinal chemistry.

[97]  Frederick Luk,et al.  Inhibition of the Multidrug Resistance P-Glycoprotein: Time for a Change of Strategy? , 2014, Drug Metabolism And Disposition.

[98]  C. Förster,et al.  In silico structure-based screening of versatile P-glycoprotein inhibitors using polynomial empirical scoring functions , 2014, Advances and applications in bioinformatics and chemistry : AABC.

[99]  A. Saneja,et al.  Advances in P-glycoprotein-based approaches for delivering anticancer drugs: pharmacokinetic perspective and clinical relevance , 2014, Expert opinion on drug delivery.

[100]  M. Zloh,et al.  Computational classification models for predicting the interaction of drugs with P-glycoprotein and breast cancer resistance protein , 2014, SAR and QSAR in environmental research.

[101]  อนิรุธ สืบสิงห์,et al.  Data Mining Practical Machine Learning Tools and Techniques , 2014 .

[102]  A. Yan,et al.  Bacterial multidrug efflux pumps: mechanisms, physiology and pharmacological exploitations. , 2014, Biochemical and biophysical research communications.

[103]  M. Pešić,et al.  Targeted Anti-Cancer Therapy, Acquiring and Overcoming Multi-Drug Resistance , 2014 .

[104]  K. Thai,et al.  QSAR Studies on Bacterial Efflux Pump Inhibitors , 2015 .

[105]  Supratik Kar,et al.  On a simple approach for determining applicability domain of QSAR models , 2015 .

[106]  Rutvija Pandya,et al.  C5.0 Algorithm to Improved Decision Tree with Feature Selection and Reduced Error Pruning , 2015 .

[107]  Kunal Roy,et al.  Importance of Applicability Domain of QSAR Models , 2015 .

[108]  K. Thai,et al.  Virtual screening for novel Staphylococcus Aureus NorA efflux pump inhibitors from natural products. , 2015, Medicinal chemistry (Shariqah (United Arab Emirates)).

[109]  K. Thai,et al.  Three- and four-class classification models for P-glycoprotein inhibitors using counter-propagation neural networks , 2015, SAR and QSAR in environmental research.

[110]  Khac-Minh Thai,et al.  Computational predictive models for P-glycoprotein inhibition of in-house chalcone derivatives and drug-bank compounds , 2016, Molecular Diversity.